Latest Industry Insights
Industry Insight
How Will Genome UK Securely Handle 150 Petabases of Genomic Data?
Genomic data company PetaGene recently sounded a warning that Genome UK, the UK government’s recently announced genomic healthcare strategy, needs to address important data handling challenges to maintain public trust. To find out more, Technology Networks spoke to PetaGene’s co-founder and chief commercial officer, Vaughan Wittorff, PhD, and co-founder and chief executive officer, Dan Greenfield, PhD.
Industry Insight
Capturing the Transcriptome and the Epigenome Simultaneously in Single Cells
How do we take our understanding of the different stages of the omics cascade to the next level? We analyze them simultaneously. With the recent launch of its Chromium Single Cell Multiome ATAC + Gene Expression solution, 10x Genomics is making advances towards that goal. Technology Networks spoke with Ben Hindson to learn more.
Industry Insight
Exploring Genetic Variation and COVID-19 Clinical Variability
One of the biggest challenges that scientists and healthcare professionals are facing during the COVID-19 pandemic is the high rate of clinical variability. Whilst some patients present as asymptomatic, others are developing more severe symptoms such as pneumonia, and some cases are ultimately proving fatal. Why? We speak with Dr Salvatore Viscomi to learn more.
Industry Insight
Addressing Key Challenges in Cell and Gene Therapy Manufacturing
Technology Networks spoke with Hugh H. Tansey, senior director of innovation and growth programs for laboratory equipment at Thermo Fisher Scientific to learn more about how the CTS Series Laboratory Equipment can deliver solutions for the key challenges in cell and gene therapy manufacturing.
Industry Insight
A New SARS-CoV-2 Descriptive Diagnostic Test – What Makes This Assay Different to Others?
Clear Labs is a company focused on the latest technologies in molecular testing, machine learning, automation and bioinformatics – it develops fully automated next-generation sequencing and in vitro diagnostics solutions. Technology Networks had the pleasure of speaking with ClearLabs’ CEO Sasan Amini, to learn more about the company’s NGS-based COVID test, Clear Dx™.
Industry Insight
Next-Generation Sequencing: Tracking the Spread and Evolution of SARS-CoV-2
This article explores how next-generation sequencing (NGS) is being used to help track the spread and evolution of SARS-CoV-2, including pinpoint the different lineages of the virus and identifying patterns of its movement both globally as well as locally.
Industry Insight
Can You Achieve Rapid MS Analysis With No Sample Prep?
News of how innovations can assist scientists and their workflows is not uncommon, but claims of “industry revolutions”, however, tend to be a little less frequent. The Echo® MS System from SCIEX is touted as being one such revolution, we spoke to Neil Walsh to learn more.
Industry Insight
A Conversation With Professor Josef Penninger on the Journey to a COVID-19 Therapeutic
The ACE2 receptor has garnered significant attention for the wrong reasons over recent months. Could it point towards an exit route out of this pandemic? In an interview with Technology Networks, the renowned immunologist Professor Josef Penninger explains why he thinks so, and discusses the latest clinical data obtained from testing the soluble ACE2 receptor, APN01.
Industry Insight
LAMP-Based Testing for COVID-19
Technology Networks recently spoke to Dr Gary Keating, Chief Technical Officer at Hibergene Diagnostics, to learn more about LAMP technology and the advantages it could offer for COVID-19 testing. Gary also discussed some of the challenges faced when developing diagnostics and how the COVID-19 pandemic has impacted diagnostic design and manufacturing.
Industry Insight
From Vaccine Printers to DNA Data Storage, What's in Store for the Future of Synthetic Biology?
Scientists are harnessing the power of synthetic biology – a field of science that involves redesigning biological components to generate novel synthetic entities – to solve scientific problems and drive innovation in medicine. Technology Networks recently spoke with Codex DNA’s CEO Todd R. Nelson to learn about the impact synthetic biology techniques are having on pharmaceutical development and the "big trends" in synthetic biology we are already seeing and are expected to see in the next few years.
Advertisement